Metabolic & Bariatric Surgery

Vol. 2, Issue 9 | September 8, 2026 | Closing the gaps in knowledge...

Editor note: This issue reflects the weekly Editorial Board ballot. Ballots were counted by Dr. Jerry Dang, MD, PhD; Phil Schauer; Samer Mattar; Shanu Kothari, MD, FACS; and Teresa LaMasters. No fallback sections were used. Section D closes with a dispatch from the IFSO World Congress floor — our thanks to Dr. Puraj Patel of Henry Ford Health, who submitted it via our IFSO field-note form. If you are at a meeting and see something the rest of us should know about, we want it.

A — Metabolic Surgery Research

Stanley, Mallik, Hamid, Jassil, Reuven, Ruwona, Dicken, Qamar, Norton, Kingett, Pucci, Magee, Boniface, Batterham, Mok, Brown, Makaronidis | Nature Medicine, 2026 | DOI source

BARI-STEP randomized 70 adults at least a year past gastric bypass or sleeve gastrectomy who had lost under 20% of their body weight to weekly semaglutide 2.4 mg or placebo, both on a modest calorie-deficit lifestyle plan. At 68 weeks, semaglutide produced 18% average weight loss against a placebo group that held steady, a gap of roughly 19 percentage points, with metabolic markers and quality-of-life measures moving favorably alongside.

Investigators presented it as a MASON Lecture at the IFSO World Congress this month, which is why an October 2025 publication is now surfacing. This is among the first placebo-controlled trials designed for patients who plateau after bariatric surgery, rather than a post hoc subset of a general obesity study, so surgeons can cite randomized evidence when a patient asks about adding an incretin. The sample is small and from a single UK center, and durability after treatment stops is untested.

KEY FINDING

In patients with suboptimal weight loss after bypass or sleeve, adding semaglutide produced an additional 18% weight reduction at 68 weeks compared with placebo, with parallel metabolic and quality-of-life gains.

Hassanesfahani, Popescu, All, Mandava, Khan, Shah | Surgery for Obesity and Related Diseases, 2026 | DOI source

This systematic review and meta-analysis compared endoscopic closure against surgical revision for gastro-gastric fistula after Roux-en-Y gastric bypass. Endoscopy was associated with fewer adverse events but achieved durable closure in only about 3 in 10 patients. Surgical revision was effective in essentially all treated cases with no recurrences in the pooled cohorts, at the cost of a more invasive recovery and higher procedural morbidity.

The evidence is a published case series rather than a head-to-head randomized comparison, so the two strategies were never tested in the same patients. The practical reading is stepwise: endoscopy is a reasonable lower-risk first attempt, particularly in poor surgical candidates, but teams should expect a real chance of failure and a later conversation about revision. Case selection, fistula size, and chronicity likely drive more of the variance than the review can isolate.

CLINICAL IMPLICATION

Endoscopic closure of gastro-gastric fistula is durable in only about 30% of cases, compared with nearly 100% with surgical revision. Frame endoscopy as a reasonable first step, not a guaranteed alternative.

Zorzano-Martínez, Switzer-Rodríguez, Bueno, Herrerías, Caixàs, Luna, Ciudin, Petrola et al. | Obesity Pillars, 2026 | DOI source

Researchers validated the OBEGEN score, which pairs clinical variables with genetic markers, in a multicenter cohort of 342 patients who underwent Roux-en-Y bypass or sleeve gastrectomy. After adjustment for baseline BMI, sex, diabetes status, and treatment center, higher scores predicted significantly greater percent total weight loss at five years. It is designed to sit alongside standard preoperative assessment, not to replace it.

A validated score has clear value in setting expectations before surgery and in flagging patients who may need earlier or more intensive adjunct therapy. Obesity Pillars is a legitimate peer-reviewed venue but sits outside the flagship bariatric journals, so independent replication in a larger cohort would strengthen confidence before routine counseling use. Genetic testing also raises questions about cost, access, and turnaround time that a single validation study cannot answer.

KEY FINDING

A clinical-genetic score predicted five-year weight-loss trajectory across 342 bypass and sleeve patients, independent of baseline BMI, sex, diabetes, and surgical center.

Kim, Schweitzer, Kim, Alexander, Mehta | JAMA Surgery, 2025 | DOI source

Using a national electronic health record network, investigators followed 112,858 adults who underwent bariatric surgery between 2015 and 2023 and found that 14% later started a GLP-1 receptor agonist. Initiation was more common among women, among patients further from surgery, and after sleeve gastrectomy than after bypass, and it rose steadily across the study years. Semaglutide was the most prescribed agent.

The analysis predates FDA approval of some current formulations and captures neither dose, adherence, nor the reason a patient started. Still, it confirms what clinics already observe: postoperative GLP-1 use is becoming a routine adjunct for residual weight or weight regain. That makes follow-up a multi-year medication-access problem as much as a surgical one, and programs that build a structured pathway to identify and refer these patients may see better long-term trajectories.

CLINICAL IMPLICATION

About 1 in 7 bariatric surgery patients in this cohort started a GLP-1 afterward, with use rising over time. Postoperative pathways should treat medication follow-up as the default, not the exception.

B — Science of Obesity Metabolism

Gallage, Govaere, Anstee, Shulman, Tacke, Heikenwalder | Nature, 2026 | DOI source

This review traces metabolic dysfunction-associated steatohepatitis from insulin resistance and excess hepatic lipid accumulation, through lipotoxic injury, adipose tissue dysfunction, and chronic inflammation, to fibrosis and, in a subset of patients, hepatocellular carcinoma. Rather than isolating the liver, the authors frame MASH as one organ's expression of a process that also involves adipose tissue, skeletal muscle and systemic inflammatory signaling.

No new trial data are presented; the value is in consolidating mechanistic literature scattered across many smaller studies. Bariatric surgeons already sit at this intersection, since a meaningful share of surgical candidates have undiagnosed MASH and surgery is among the more effective treatments for it. The multi-organ mechanism explains why weight loss so reliably improves liver histology: it interrupts the process at several points rather than one.

CLINICAL IMPLICATION

MASH is best understood as a systemic metabolic disease with hepatic consequences, not a liver-only condition. That supports treating it as a core indication for weight-loss therapy rather than an incidental finding.

Emptage, Kozmer, Cobham-Wilson, Sousa, Sugden, Wheeler, Llewellyn, Makaronidis, Bulik, Solmi, Costantini | eClinicalMedicine, 2026 | DOI source

This systematic review and meta-analysis pooled 25 randomized trials and more than 8,000 participants with obesity to test whether GLP-1 receptor agonists reduce binge-eating symptoms. The pooled evidence supports a meaningful reduction in binge-eating frequency and severity, a signal holding up across trials not originally designed to study eating behavior as a primary endpoint.

Binge-eating patterns are common among bariatric candidates and predict poorer postoperative weight trajectories when they persist or recur. A drug class improving both weight and binge symptoms strengthens the case for early or perioperative GLP-1 use in patients screening positive for disordered eating, alongside behavioral treatment. Because most trials were not built to measure eating pathology, this remains a secondary signal rather than a confirmed indication.

KEY FINDING

Pooled data across 25 randomized trials found that GLP-1 receptor agonists reduced binge-eating symptoms in patients with obesity, suggesting a behavioral effect independent of weight loss alone.

Gallagher, Razura, Li, Kim, Vukkadala, Barbu | JAMA Otolaryngology–Head & Neck Surgery, 2026 | DOI source

Using electronic health record data from 70 health systems, investigators compared more than 427,000 patients with type 2 diabetes prescribed a GLP-1 receptor agonist against roughly 1.6 million prescribed a different second-line diabetes medication. After propensity matching, GLP-1 users had a 12% higher relative risk of a new chronic cough diagnosis within five years, and the association persisted more strongly in patients without documented reflux.

This is an observational signal, not proof of causation, and the population was patients with diabetes rather than the postsurgical or GLP-1-for-obesity group surgeons see most often. Still, chronic cough is common enough, and frustrating enough for patients, to be worth adding to tolerability counseling for anyone starting a GLP-1 in a surgical weight-management pathway. Consider the medication before reflexively attributing it to reflux.

CLINICAL IMPLICATION

Chronic cough emerged as a hypothesis-generating GLP-1 side effect independent of reflux status. Ask about cough when reviewing tolerability, and don't assume reflux explains every case.

Horn, Shukla, Huang, Twum, Allen, Kis et al. | Obesity Pillars, 2026 | DOI source

A post hoc analysis of the ATTAIN-1 and ATTAIN-2 trials examined 613 treated participants aged 65 and older who received once-daily oral orforglipron at one of three doses or placebo. At 72 weeks, weight reduction ranged from about 7.5% to 13% across doses, comparable to or slightly better than that observed in younger participants, with all doses significantly better than placebo. Safety matched the overall trial populations.

As an industry-sponsored subgroup analysis, it was not powered or designed as a standalone trial in older adults. Still, age has long been a soft barrier to aggressive obesity pharmacotherapy, and comparable performance past 65 matters for programs managing older candidates who may prefer a pill to an injection, or who are weighed for medical rather than surgical treatment given age-related risk. It should inform those decisions, not settle them.

CLINICAL IMPLICATION

Oral orforglipron produced 7.5-13% weight loss in adults aged 65 and older, with safety similar to that in younger patients. Age alone should not exclude older candidates from oral incretin therapy.

C — Metabolic Innovation and Technology

Regalado | MIT Technology Review, 2026 | Source ↗

MIT Technology Review examines the gap between how AI drug-discovery companies describe their platforms and how those same companies file patents. Insilico Medicine publicly credits its generative AI platform with discovering a pulmonary fibrosis candidate, yet its filing names five human scientists as inventors — a split tracing to a 2022 federal appeals court ruling that inventorship under U.S. law requires a human being.

The U.S. Patent and Trademark Office has acknowledged the mismatch as AI takes on more of the discovery work, and one patent attorney put it plainly: "There needs to be a human inventor, or there's no invention and no patent." The connection to bariatric surgery is indirect but real: unresolved inventorship questions could shape which companies get funded and how fast obesity and MASH therapies reach patients.

CLINICAL IMPLICATION

Patent law still requires a human inventor even when AI drives the underlying discovery. That unresolved question could influence investment and timelines for the next wave of metabolic therapeutics.

Noel, Biertho, Ponce, Garneau, Lutfi, Gagner | Surgery for Obesity and Related Diseases, 2026 | DOI source

This systematic review and meta-analysis pooled early clinical experience with duodeno-ileal magnetic compression anastomosis, a sutureless technique using paired magnets to create a bowel connection without staples or hand-sewn anastomosis. Across small prospective cohorts, feasibility was encouraging with a low signal for device-related leak, though studies varied considerably in patient selection and procedural context.

The authors describe the certainty of the evidence as low to very low, given the size and design of the available studies. It is one of several device-based attempts to reduce the technical complexity and leak risk of intestinal reconstruction, but feasibility data are not a comparative trial against stapled or hand-sewn technique, and efficacy varied by how and where the device was used. Treat this as investigational-stage evidence.

KEY FINDING

Duodeno-ileal magnetic compression anastomosis showed low device-related leak rates in small early cohorts, but evidence certainty remains low, and efficacy varies by procedural context.

FDA 510(k) database | FDA 510(k) Premarket Notification, 2026 | FDA record

The FDA's 510(k) database lists clearance (K243968) for the Revolve Surgical System, an electromechanically controlled laparoscopic platform indicated for minimally invasive abdominal surgery. It is table-mounted rather than a standalone, cart-based robot, with a reusable arm that attaches to the operating table and manipulates tissue under the surgeon's direct control.

The clearance covers a general surgery indication, and the manufacturer, a Toronto-based startup, intends to pursue expanded clearance across laparoscopic procedures before a broader launch. It is notable mainly for what it is not: another large cart-based system competing on cost and footprint. The clearance says nothing about comparative outcomes or bariatric-specific performance, so wait for procedure-specific data.

CLINICAL IMPLICATION

A newly cleared table-mounted robotic platform could lower cost and space barriers for smaller programs, but general-surgery clearance does not demonstrate bariatric-specific performance.

Foula, Bamalan, Foula, Eldamati, Alratrout, AlQatari, Alsaleem, Aldabaeab et al. | Obesity Surgery, 2026 | DOI source

This PRISMA-guided systematic review screened the literature, yielding 88 studies describing artificial intelligence applications across the bariatric surgery pathway, categorized into preoperative risk prediction, intraoperative guidance, postoperative monitoring, and emerging large-language-model uses such as patient education and documentation support.

It is a landscape map rather than a performance comparison, and the authors are explicit that published evidence supporting clinical adoption remains limited relative to the activity underway. The practical message is that AI here is still mostly pilot studies and single-center models. Preoperative risk calculators and postoperative monitoring are the most mature categories; intraoperative guidance and language-model applications are at an earlier stage.

CLINICAL IMPLICATION

Across 88 studies, AI applications in bariatric surgery remain concentrated in preoperative and postoperative use cases, with evidence still too thin to support broad clinical adoption.

D — Metabolic Marketplace

Forbes Health | Forbes Health, 2026 | Source ↗

Forbes Health models how rising GLP-1 adoption is reshaping consumer spending on groceries, restaurants, and packaged food, drawing on industry estimates projecting tens of billions of dollars in lost annual food and beverage sales. It describes shifts already visible in retail and restaurant data, including reduced spending on sugary drinks and impulse snacks, alongside reformulation toward smaller portions and higher protein content.

This is a consumer-spending analysis, not clinical evidence, but it shows how thoroughly GLP-1 use is priced into forecasts for a completely different industry. Patients arriving for surgical consultation increasingly come from a market already responding to incretin-driven behavior change, which shapes what they expect medication to do for them before an operation is ever discussed.

MARKET WATCH

Industry models project GLP-1 adoption could remove tens of billions of dollars from annual U.S. food and beverage sales, evidence of how deeply incretin use is reshaping behavior beyond the clinic.

Michael Erman / Reuters | Reuters, 2026 | Source ↗

Reuters reports that 600,000 seniors enrolled in the Medicare Bridge program for access to GLP-1 weight-loss medications in the first two months of the program, a federal initiative launched in July that lets qualifying older adults obtain obesity medications for a flat $50 monthly copay. CMS Administrator Dr. Mehmet Oz announced the figures, describing an effort to expand access for a population Medicare has historically not covered for obesity drugs.

Coverage removes a major access barrier that kept many older patients out of the GLP-1 market entirely, and 600,000 enrollees in two months suggest substantial pent-up demand. For bariatric programs, it changes the referral calculus for older patients who previously had few affordable options short of surgery, and it shapes how many arrive at consultation having already tried, tolerated, or failed medication.

MARKET WATCH

Medicare's new $50-a-month Bridge program drew 600,000 senior enrollees in its first two months, a shift that will change how many older patients already on GLP-1 therapy reach surgical consultation.

Patricia Weiss, Bhanvi Satija, Louise Rasmussen / Reuters | Reuters, 2026 | Source ↗

Reuters reports that Novo Nordisk has launched its oral Wegovy pill in Germany, the first European Union market for the product, following a positive recommendation from the European Medicines Agency in May and clearance from the European Commission in July. Pricing varies by dose but is expected to land near the injectable Wegovy pen, which retails between roughly €170 and €280 per month in pharmacies.

Eli Lilly's competing pill launched in the UK in late August and is under regulatory review in more than 40 additional markets. An oral option removes the injection barrier that deters some patients from starting or continuing therapy, and a first EU launch sets the pace for how quickly oral incretins will spread. For programs outside the U.S., pen-comparable pricing changes the practical calculus around access.

MARKET WATCH

Novo Nordisk's oral Wegovy pill is now available in Germany, its first EU launch, at pricing comparable to the injectable pen, intensifying competition with Lilly's rival oral product.

Dr. Puraj Patel, Henry Ford Health | IFSO World Congress 2026 | Send us a finding ↗

Dr. Puraj Patel of Henry Ford Health wrote in from the IFSO World Congress about a session on magnetic anastomosis presented by Dr. Tammy Kindel, which reported weight loss after magnetic duodeno-ileal anastomosis performed as a primary operation compared with the same procedure performed as a revision. The revision arm caught his attention: 16-17% excess weight loss in patients who had already undergone sleeve gastrectomy.

He described it as "an interesting alternative to conversion to bypass for failed weight loss after sleeve." Podium figures are preliminary and have not come through peer review, so read them as direction rather than result.

FROM THE FIELD

Magnetic duodeno-ileal anastomosis performed after a prior sleeve resulted in 16-17% excess weight loss, per data presented at IFSO 2026. Preliminary and not yet peer-reviewed.

Production Editor: John D. Scott, MD, FACS | [email protected]

We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected].

The MBS Digest | September 8, 2026 | Vol. 2, Issue 9 | For Educational Purposes Only | Not for Redistribution